Background: Atrial fibrillation (AF) is one of the most common complications after coronary artery bypass grafting (CABG), and the incidence of postoperative AF (PAF) is estimated to range from 10% to 40%. PAF is a serious complication that is related to unstable hemodynamics, development of embolisms, patient discomfort, and increased medical costs associated with the prolongation of hospital stay. Sometimes, immediate attention is also necessary. In this study, we assessed the efficacy of treatment with the antiarrhythmic drug propafenone hydrochloride, which was administered in the early postoperative period, in preventing the development of PAF, and we attempted to identify risk factors for PAF.

Materials And Methods: The subjects were 78 patients who underwent isolated off-pump CABG between July 2007 and October 2008. We conducted the study by dividing the patients into 2 groups, a group of 26 patients who received propafenone hydrochloride (P group) and a control group of 52 patients who did not receive this drug (C group). The patients in the P group were given propafenone hydrochloride (150-450 mg/day orally) for 10 days, starting on the day after surgery, and were observed for the development of AF by means of continuous 12-lead electrocardiographic monitoring. Development of AF was defined as AF that lasted
Results: The background factors of the patients in the P and C groups were similar. The operation times and the numbers of distal anastomoses in the 2 groups were similar, and there were no particular differences between the 2 groups with respect to postoperative factors. The incidence of PAF was 35% in the C group and significantly lower in the P group (12%, P = .0337). Moreover, multiple logistic regression analysis showed that propafenone hydrochloride was the sole factor that prevented the development of PAF (odds ratio, 0.207; 95% confidence interval, 0.053-0.804; P = .0229).

Conclusion: Cases must be carefully considered before administering propafenone hydrochloride, but the results of this study indicate that propafenone hydrochloride may prevent the development of PAF.

Download full-text PDF

Source
http://dx.doi.org/10.1532/HSF98.20091173DOI Listing

Publication Analysis

Top Keywords

propafenone hydrochloride
16
group patients
12
atrial fibrillation
8
coronary artery
8
artery bypass
8
bypass grafting
8
patients
5
group
5
efficacy propafenone
4
hydrochloride
4

Similar Publications

Background: Flecainide and other class-Ic antiarrhythmic drugs (AADs) are widely used in Andersen-Tawil syndrome type 1 (ATS1) patients. However, class-Ic drugs might be proarrhythmic in some cases. We investigated the molecular mechanisms of class-I AADs proarrhythmia and whether they might increase the risk of death in ATS1 patients with structurally normal hearts.

View Article and Find Full Text PDF

Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma.

J Immunother Cancer

November 2024

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China

Article Synopsis
  • * Researchers screened 200 FDA-approved cardiovascular drugs and identified propafenone, a heart medication, as a potential enhancer of ferroptosis in melanoma treatment.
  • * Results showed that combining propafenone with ferroptosis inducers leads to significant tumor regression and improved survival rates in animal models, suggesting its potential to boost immunotherapy responses in melanoma patients.
View Article and Find Full Text PDF
Article Synopsis
  • - The study focused on 12 children diagnosed with catecholaminergic polymorphic ventricular tachycardia (CPVT), investigating their long-term health outcomes, including how they responded to treatments and the incidence of heart-related events over a follow-up period of about 20 years.
  • - Despite beta-blocker therapy, a significant number of patients continued to experience syncope and supraventricular tachycardia (SVT), indicating that the risk of cardiac events remains high, even with treatment.
  • - Genetic testing revealed mutations in several patients, highlighting the importance of personalized treatment strategies, and suggesting that combining beta-blockers with antiarrhythmic medications might be beneficial for managing CPVT.
View Article and Find Full Text PDF

Background: This study investigated drug-drug interactions in patients with atrial fibrillation taking both a direct oral anticoagulant (DOAC) and an antiarrhythmic drug.

Methods And Results: Using data from the National Health Insurance database (2012-2018), we identified 78 805 patients with atrial fibrillation on DOACs, with 24 142 taking amiodarone, 8631 taking propafenone, 2784 taking dronedarone, 297 taking flecainide, 177 taking sotalol, and 42 772 on DOACs alone. Patients with bradycardia, heart block, heart failure, mitral stenosis, prosthetic valves, or incomplete data were excluded.

View Article and Find Full Text PDF

Development of new K2.1 channel openers from propafenone analogues.

Br J Pharmacol

October 2024

Department of Medical Physiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands.

Article Synopsis
  • Reduced functioning of the K2.1 potassium channel is linked to conditions like heart failure and Andersen-Tawil Syndrome, making it crucial to find treatments that specifically target this channel, as current therapies do not.
  • Research analyzed the effects of propafenone and its analogues on the K2.1 channel using techniques like patch-clamp electrophysiology and western blot analysis, highlighting the potential of these compounds to improve potassium current.
  • Notably, the analogue GPV0057 increased the potassium current without blocking it at low concentrations, suggesting it could be a viable treatment option for diseases related to K2.1 deficiency.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!